Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) Net Income towards Common Stockholders (2019 - 2026)

Alx Oncology Holdings' Net Income towards Common Stockholders history spans 5 years, with the latest figure at $91.1 million for Q4 2023.

  • On a quarterly basis, Net Income towards Common Stockholders rose 28.49% to $91.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$24.7 million, a 12.83% decrease, with the full-year FY2025 number at -$497000.0, up 99.63% from a year prior.
  • Net Income towards Common Stockholders hit $91.1 million in Q4 2023 for Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ALXO hit a ceiling of $91.1 million in Q4 2023 and a floor of -$51.0 million in Q3 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$10.5 million across 5 years, with a median of -$16.3 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 169.83% in 2020 and later skyrocketed 349.23% in 2022.
  • Tracing ALXO's Net Income towards Common Stockholders over 5 years: stood at -$8.8 million in 2019, then tumbled by 112.5% to -$18.8 million in 2020, then tumbled by 51.48% to -$28.4 million in 2021, then skyrocketed by 349.23% to $70.9 million in 2022, then grew by 28.49% to $91.1 million in 2023.
  • Business Quant data shows Net Income towards Common Stockholders for ALXO at $91.1 million in Q4 2023, -$51.0 million in Q3 2023, and -$34.5 million in Q2 2023.